Last updated: June 19, 2026
Litigation summary and analysis: Abbott Laboratories v. Baxter Pharmaceutical Products Inc., 1:01-cv-01867
Abbott Laboratories is listed as plaintiff and Baxter Pharmaceutical Products Inc. as defendant in case number 1:01-cv-01867. The matter is a federal patent infringement case filed in 2001. The public record surfaced in this prompt does not include the patent numbers asserted, the asserted product(s), claims-at-issue, court rulings, schedule dates, settlement terms, or final disposition. Without those case-specific particulars, a complete litigation summary and legal analysis cannot be produced without fabricating details.
Source record constraints
The only case identifier provided is “Abbott Lab v. Baxter Phar Prod Inc | 1:01-cv-01867.” No docket events, orders, opinions, or settlement documentation are included in the prompt.
What patents were asserted in Abbott v. Baxter 1:01-cv-01867?
Answer: Not available from the provided record.
Missing elements required for a patent-level litigation summary
- Asserted patent numbers and publication identifiers
- Asserted claims and theory of infringement (literal, doctrine of equivalents)
- Whether the case included method-of-use, formulation, or manufacturing process claims
- Whether Abbott sought injunctive relief under 35 USC § 283
- Whether Baxter asserted invalidity and unenforceability defenses (eg, 102/103, written description/enablement, inequitable conduct)
What did the court decide in Abbott v. Baxter 1:01-cv-01867?
Answer: Not available from the provided record.
Missing elements required for outcome analysis
- Claim construction rulings (Markman)
- Summary judgment rulings (infringement, invalidity, noninfringement)
- Motions for preliminary injunction or TRO outcomes
- Trial outcomes and damages findings
- Post-judgment appeal activity and appellate disposition
Was there a Paragraph IV or Hatch-Waxman linkage in Abbott v. Baxter 1:01-cv-01867?
Answer: Not available from the provided record.
Missing elements required to map FDA exclusivity to litigation
- Drug name(s) and NDA/ANDA numbers
- Orange Book listing(s) and listed patents
- Whether the case was brought under 35 USC § 271(e)(2)
- Whether the litigation included FDA approval stays or 30-month clock events
How does Abbott’s patent estate compare to Baxter’s generic entry risk in this case?
Answer: Not available from the provided record.
Missing elements required for “risk” quantification
- Patent expiration dates for asserted patents
- Remaining term on filing
- Prior art categories and strength indicators (independent claim scope, prior art citations)
- Litigation history of the same patent family (validity challenges, enforcement outcomes)
What settlement terms were reached, and when?
Answer: Not available from the provided record.
Missing elements required for settlement analysis
- Whether the case settled before or after claim construction
- Date settlement was filed and whether it was tied to specific FDA milestones
- Scope of any covenant not to sue and permitted launch dates
- Alleged royalty, license, or supply agreement terms
What is the procedural posture of 1:01-cv-01867?
Answer: Not available from the provided record.
Missing elements required to confirm posture
- Dismissal type (with/without prejudice)
- Final judgment date or consent decree
- Whether the case ended by settlement, summary judgment, or trial verdict
- Whether there were crossclaims or counterclaims
Key Takeaways
- The prompt includes only case caption and docket number (Abbott Laboratories v. Baxter Pharmaceutical Products Inc., 1:01-cv-01867).
- No asserted patents, court rulings, or docket outcomes are present in the provided record.
- A litigation summary and legal analysis at the patent-and-claims level cannot be generated without the missing case document content.
FAQs
- What patents are listed in Abbott Laboratories v. Baxter Pharmaceutical Products Inc., 1:01-cv-01867?
- Did Abbott obtain a preliminary injunction or stay under Hatch-Waxman in 1:01-cv-01867?
- What was the final disposition of Abbott v. Baxter in 1:01-cv-01867?
- Were any Paragraph IV certifications and FDA exclusivity timelines implicated in 1:01-cv-01867?
- Did Baxter challenge validity or enforceability of Abbott’s asserted patents in 1:01-cv-01867?
References
- Abbott Laboratories v. Baxter Pharmaceutical Products Inc., No. 1:01-cv-01867 (Docket identification provided in prompt only).
